Clinical utility of anti-interleukin 5 monoclonal therapy in asthma using a national, centralised, outcome-based system of drug access
Sign Up to like & getrecommendations! Published in 2022 at "BMJ Open Respiratory Research"
DOI: 10.1136/bmjresp-2022-001341
Abstract: Introduction Interleukin 5 (IL-5) inhibitors are an important therapeutic advance in the management of severe, refractory, eosinophilic asthma. However, their utilisation should be targeted to maximise their benefits. This study used multisite, centralised, national data… read more here.
Keywords: utility anti; asthma; therapy; monoclonal therapy ... See more keywords
Nasal vaccine or monoclonal therapy: Which is winning weapon against SARS-CoV-2 variants in 2022?
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Global Health"
DOI: 10.7189/jogh.12.03023
Abstract: the coronavirus transformations are harmless. The Alpha variant had already distinguished itself for the greater speed of contagion compared to the original SARS-CoV-2 virus; the Beta affected younger subjects, between 10 and 30 years; Gamma… read more here.
Keywords: nasal vaccine; vaccine monoclonal; winning weapon; monoclonal therapy ... See more keywords